The Bladder Cancer Company

Our Company

About Us

Our Values

Our History

Bladder cancer challenge

Leadership

Board of directors

Executive Leadership

Innovation & Products

Precision Diagnostics

Our products

Research support

News

Our Perspective

The Importance of Health Economics​

Bladder Cancer and AI

Addressing Inequality

Our Impact

Patient Registries And Real-World Evidence

Bladder cancer community support

Corporate social responsibility

ESG Report

Partners

Why Partner with Photocure

Our Partners

Careers

Photocure culture

Working at Photocure

Contact

Investors hub

Events & Presentations

Financials

Shareholder information

FAQs

Investors

Press & Media

Privacy Policy

Terms of use

cevira

large_shareholders.png

medium_shareholders.png

small_shareholders.png

thumbnail_shareholders.png

Shareholders

ESG report

Photocure ASA: Notification of primary insider transactions

Photocure ASA - Share option grant to members of the board of directors

Photocure ASA: Asieris counterclaim on milestone payment arbitration

Photocure ASA - Share option grant

Photocure ASA: Results for the second quarter of 2026

Photocure ASA: Invitation to presentation of second quarter 2026 financial results

Photocure ASA – CFO transition

Photocure ASA: Annual general meeting held

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day

Product Announcements

Partnership News & Expansion

Photocure ASA - Notice of the Annual General Meeting 26 June 2026

Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

Investor conferences

Financial Investment & Stock

Organisational Announcements

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

Medical congresses & events

Medical Information

Patient Registries

Real World Evidence

Photocure ASA: Results for the first quarter of 2026

New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer

<p>We use cookies to provide the best possible experience for you. By closing this message you agree to our use of cookies. You can learn more about cookies on our <a href="https://photocure.com/privacy-policy" target="_blank" rel="noopener noreferrer">privacy page</a>.</p>

agree

Shareholders

Investor news